The BioMarin internship programme will enable students to gain valuable experience and knowledge of the processes and systems within BioMarin, whilst gaining an insight into the pharmaceutical/biotech industry. The internship programme will start on Monday 10th June 2019 to the 30th August 2019, lasting 12 weeks in the London Office and will be full time.
The Intern will support one or more BioMarin compounds, contributing to our understanding of the Epidemiology of the disease, and helping to support planning, implementation or reporting of scientifically robust observational research projects.
Eligible candidates must have the right to work in the UK; relocation not provided.
Duties of the intern will include: •Perform literature reviews and critically appraise existing epidemiology evidence to improve disease understanding relevant to target patient populations: incidence, prevalence, risk factors, natural history disease course, burden of illness, treatment patterns, co-morbidities, co-medications, outcomes measures, phenotypes, biomarkers and unmet need, and their variations across demographics and geographies •Assist with interpretation of study results and create tables and figures to best display findings; draft final study reports to communicate research findings •Assist in creating new evidence through drafting specific research protocols and analysis of large healthcare databases
•Studying towards, or recently completed, a Master’s degree in Epidemiology •Self-motivated with the ability to work independently •Ability to balance priorities and handle multiple tasks through careful planning •Excellent oral and written communication skills and ability to communicate scientific evidence to peers •Experience in the epidemiology of rare diseases or genetic epidemiology a benefit but not required
Additional Salary Information: Competitive Salary
Internal Number: 20888
BioMarin is a world leader in developing and commercializing innovative biopharmaceuticals for rare diseases driven by genetic causes
At BioMarin, we focus on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored.
Since its foundation in 1997, BioMarin has brought 6 products to market, with 7 more in the pipeline, over half a billion dollars of revenue and a global footprint in 40 countries. We are a recognized industry leader in rare disease development.